[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Yokoyama M, Nakao Y, Iwasaka T, Pater A, Sugimori H: Retinoic acid and interferon-alpha effects on cell growth and differentiation in cervical carcinoma cell lines. Obstet Gynecol; 2001 Aug;98(2):332-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid and interferon-alpha effects on cell growth and differentiation in cervical carcinoma cell lines.
  • OBJECTIVE: To investigate and compare the efficacy of all-trans retinoic acid (RA) and/or interferon-alpha (IFN-alpha) on premalignant and malignant models of cervical cancer.
  • METHODS: Cell growth rate was examined after treatment for 4, 7, and 10 days with RA and/or IFN-alpha of human papillomavirus type 18 (HPV 18)-immortalized endo- and ectocervical cells, nontransformed serum-adapted cells, transformed cells, three adenocarcinoma, and three squamous cell carcinoma cell lines.
  • In rafts, RA treatment reversed human endocervical cell metaplasia and HPV 18-immortalized endo- and ectocervical cell dysplastic epithelial differentiation.
  • CONCLUSION: Cell growth inhibition by treatment with RA, IFN-alpha, and their combination differentially depends on treatment type and time, cell origin, cell line, and oncogenic state.
  • In a premalignant model of cervical carcinoma, RA reduces dysplastic differentiation and IFN-alpha induces apoptosis.
  • These data confirm that these treatments may be effective for preventing or treating premalignant cervical lesions.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Interferon-alpha / pharmacology. Tretinoin / pharmacology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Apoptosis / drug effects. Carcinoma, Squamous Cell / pathology. Cell Differentiation / drug effects. Cell Division / drug effects. Cell Line, Transformed. Cervix Uteri / cytology. Cervix Uteri / drug effects. Female. Humans. Papillomaviridae. Tumor Cells, Cultured / drug effects


2. Haie-Meder C, Lhommé C, de Crevoisier R, Morice P, Resbeut M: [Concomitant radiochemotherapy in cancer of the cervix uteri: modifications of the standards]. Cancer Radiother; 2000 Nov;4 Suppl 1:134s-140s
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concomitant radiochemotherapy in cancer of the cervix uteri: modifications of the standards].
  • [Transliterated title] Radiochimiothérapie concomitante dans les cancers du col de l'utérus: modifications des standards.
  • For a long time, combined external irradiation and brachytherapy has been considered as the standard treatment in patients with advanced cervical cancers.
  • The differences, however, were less significant in patients with advanced stages III or IVA.
  • The results of these randomized trials have led to a modification in the standard of treatment in these poor prognosis cervix cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Hydroxyurea / administration & dosage. Hysterectomy. Metaplasia. Neoplasm Staging. Patient Selection. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11194951.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 17
  •  go-up   go-down


Advertisement
3. Brändlein S, Pohle T, Vollmers C, Wozniak E, Ruoff N, Müller-Hermelink HK, Vollmers HP: CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep; 2004 Apr;11(4):777-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.
  • Both, the unique tumor-specific expression of the CFR-1/PAM-1 receptor and the growth inhibitory effect of the PAM-1 antibody makes this combination a good diagnostic and therapeutic tool for all kinds of epithelial cancers and precursor lesions.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Apoptosis. Carcinoma / drug therapy. Receptors, Cell Surface / antagonists & inhibitors. Sialoglycoproteins / antagonists & inhibitors
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Biological Assay. Cell Line, Tumor. Humans. Immunochemistry. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Pepsin A / chemistry. Receptors, Fibroblast Growth Factor. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncol Rep. 2004 Jul;12(1):201
  • (PMID = 15010872.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / PAM-1 monoclonal antibody, human; 0 / Receptors, Cell Surface; 0 / Receptors, Fibroblast Growth Factor; 0 / Sialoglycoproteins; 0 / cysteine-rich fibroblast growth factor receptor; EC 3.4.23.1 / Pepsin A
  •  go-up   go-down






Advertisement